Key Takeaways Amgen completed MARITIME-1 and -2 enrollment, testing MariTide in 5,000 obesity patients.MariTide aims for monthly or less frequent dosing, showing sustained weight loss in studies.NVO won FDA approval for an oral Wegovy pill, raising competition as oral GLP-1s enter weight management.Amgen (AMGN) is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing MariTide, an investigational GLP-1/GIP receptor agonist, as part of its comprehensive MARITI ...